Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 4,171 shares, a decline of 75.2% from the July 30th total of 16,792 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 8,523 shares, the short-interest ratio is currently 0.5 days.

Pulmatrix Trading Down 0.3%

Shares of NASDAQ PULM traded down $0.01 on Thursday, reaching $1.52. 14,050 shares of the company traded hands, compared to its average volume of 11,902. Pulmatrix has a fifty-two week low of $1.16 and a fifty-two week high of $5.50. The company has a 50 day moving average of $1.64 and a 200 day moving average of $1.69. The stock has a market capitalization of $5.55 million, a PE ratio of -1.38 and a beta of 1.91.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.71.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PULM. BlackRock Inc. bought a new stake in shares of Pulmatrix in the 2nd quarter worth $93,000. DRW Securities LLC acquired a new stake in shares of Pulmatrix in the 4th quarter valued at $46,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Pulmatrix in the third quarter worth $52,000. 11.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).